COMPARING DOCETAXEL PLUS CISPLATIN WITH PACLITAXEL PLUS CARBOPLATIN IN CHEMOTHERAPY-NAIVE PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER: A SINGLE INSTITUTE STUDY

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

KHODADAD KIAN; KHOSRAVI ADNAN; ESFAHANI MONFARED ZAHRA; KARIMI SHIRIN; SEIFI SHARAREH

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Iranian Journal of Pharmaceutical Research Year:2014 | Volume:13 | Issue:2 Page(s): 575-581

Download Full-Text

View:

241

Download:

112

Cites:

Information Journal Paper

Title

COMPARING DOCETAXEL PLUS CISPLATIN WITH PACLITAXEL PLUS CARBOPLATIN IN CHEMOTHERAPY-NAIVE PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER: A SINGLE INSTITUTE STUDY

Author(s)

Keywords

DOCETAXEL

PACLITAXEL

NON-SMALL CELL

LUNG CANCER

Abstract

The backbone of treatment in advanced NON-SMALL CELL LUNG CANCER is platinum-based doublet chemotherapy. We intended to compare the effectiveness of two commonly used regimens in real world practice.This single institute, parallel comparative post marketing study included 100 patients with chemo-naive advanced (stage IIIB, IV) NON-SMALL CELL LUNG CANCER and Eastern Cooperative Oncology Group performance status of 0 to 2. They were randomly assigned by stratified blocks to receive DOCETAXEL/ Cisplatin (DC, n=50) on day 1 or PACLITAXEL/Carboplatin AUC 5 (PC, n=50) on day 1, every 3 weeks for up to six cycles. Primary end point was progression free survival (PFS); secondary end points were objective response rate, overall survival (OS) and toxicity. The administered dosage could be modified according to clinician’s discretion for each individual patient.PFS was similar between DC and PC arms (4.5±0.3 v 4.6±1.8 months, respectively; HR=1.337; 95% CI: 0.874 to 2.046, P=0.181). Although median overall survival for DC arm was longer (17.2±4.4 m) than PC arm (10.6±0.7 m) but was not statistically significant (P=0.300). The 1-year survival rates were in favor of DC arm (53.1% v 37.9%). Objective response rates were similar in both groups. In our study, hematologic toxicity and neuropathy were more frequent in DC and PC arms, respectively.In our study two commonly used regimens of DC and PC showed statistically similar outcomes in terms of PFS and OS, albeit numerically results of OS and 1-year survival were in favor of DC arm.

Cites

No record.

References

No record.

Cite

APA: Copy

KHODADAD, KIAN, KHOSRAVI, ADNAN, ESFAHANI MONFARED, ZAHRA, KARIMI, SHIRIN, & SEIFI, SHARAREH. (2014). COMPARING DOCETAXEL PLUS CISPLATIN WITH PACLITAXEL PLUS CARBOPLATIN IN CHEMOTHERAPY-NAIVE PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER: A SINGLE INSTITUTE STUDY. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR), 13(2), 575-581. SID. https://sid.ir/paper/288226/en

Vancouver: Copy

KHODADAD KIAN, KHOSRAVI ADNAN, ESFAHANI MONFARED ZAHRA, KARIMI SHIRIN, SEIFI SHARAREH. COMPARING DOCETAXEL PLUS CISPLATIN WITH PACLITAXEL PLUS CARBOPLATIN IN CHEMOTHERAPY-NAIVE PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER: A SINGLE INSTITUTE STUDY. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR)[Internet]. 2014;13(2):575-581. Available from: https://sid.ir/paper/288226/en

IEEE: Copy

KIAN KHODADAD, ADNAN KHOSRAVI, ZAHRA ESFAHANI MONFARED, SHIRIN KARIMI, and SHARAREH SEIFI, “COMPARING DOCETAXEL PLUS CISPLATIN WITH PACLITAXEL PLUS CARBOPLATIN IN CHEMOTHERAPY-NAIVE PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER: A SINGLE INSTITUTE STUDY,” IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR), vol. 13, no. 2, pp. 575–581, 2014, [Online]. Available: https://sid.ir/paper/288226/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops